3m Innovative Properties Company

Medicis Pharmaceutical Corporation

Meda Ab

Richard L Miller

James H Lee

Raymond D Skwierczynski

Zheng Jane Li

Mark A Tomai

Kenneth R Phares

Mary L Owens

Michael J Jozwiakowski

Terri F Busch

Paul D Wightman

Ross M Kedl

Terrance L Fox

James D Stoesz

Christopher J Harrison

David I Bernstein

Ronnie Ortiz

Isidro Angelo Eleazar Zarraga

David E Spaner

Anthony A Gaspari

Joseph A Gillis

Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Methods and compositions for enhancing immune response

Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.

Methods of improving skin quality

Golf setup training device

The present invention provides methods for increasing expression of cell surface molecules of CD5B cell lymphoma cells by contacting cells with immune response modifiers. The invention also provides methods for the treatment of CD5B cell lymphomas, including chronic lymphocytic leukemia and small lymphocytic lymphoma, by administering immune response modifier compounds to a subject in need of such treatment. Suitable immune response modifier compounds include agonists of TLR7 and/or TLR8.

[object Object]

Methods for diagnosing skin lesions are disclosed. Generally, the method include topically administering an IRM compound to a treatment area for a period of time and in an amount effective to cause a visible change in the appearance of a skin lesion including, in some cases, causing subclinical lesions to become visible. Suitable IRM compounds include agonists of one or more TLRs.

Methods for treating skin lesions

Methods of preventing and/or treating UV-induced immunosuppression by administration of immune response modifier compounds are disclosed herein. Suitable immune response modifier compounds include agonists of one or more TLRs.

Method of reducing and treating UVB-induced immunosuppression

Immune response modifier (IRM) compounds&mdash;imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo- and oxazolo-quinolinamines and pyridinamines, imidazonaphthyridine and tetrahydroimidazonaphthyridine amines&mdash;are useful for the treatment of conditions at and below the mucosal surfaces by administering a therapeutically effective amount of such compounds to the mucosal surface. Novel pharmaceutical formulations are provided. In one embodiment, the pharmaceutical formulations are advantageous for treatment of cervical conditions such as cervical dysplasias including cervical intraepithelial neoplasias.

Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

An immunogen/vaccine adjuvant composition containing an immunogen in an amount effective to stimulate an immune response and as a vaccine adjuvant a 1H-imidazo[4,5-c]quinolin-4-amine in an amount effective to increase the immune response to the immunogen.

1H-imidazo[4,5-C]quinolin-4-amines as vaccine adjuvants

Chair or similar article

Base for a lamp

Growing community of inventors

Maplewood, MN, United States of America

Richard L Miller